Evidence map›Paper›PMID 25676417›Full record

ArticleLeukemia2015

Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia.

C N Hahn, P J Brautigan, C-E Chong, A Janssan, P Venugopal, Y Lee, A E Tims, M S Horwitz, M Klingler-Hoffmann, H S Scott

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Heterogeneity of GATA2-related myeloid neoplasms.International journal of hematology · 2017
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

C N Hahn1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
P J Brautigan1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
C-E Chong1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia.
A Janssan1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.
P Venugopal1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Y Lee1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
A E Tims1] Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA [2] Seattle Children's Research Institute, Seattle, WA, USA.
M S HorwitzDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.
M Klingler-Hoffmann1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.
H S Scott1] Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia [2] Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia [3] School of Medicine, University of Adelaide, Adelaide, South Australia, Australia [4] School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia [5] School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia [6] ACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, South Australia, Australia.
South Australia Pathology · AUUniversity of Washington · USUniversity of South Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blotting, WesternFemaleGATA2 Transcription FactorGerm-Line MutationHEK293 CellsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesPedigreeResponse ElementsThrombocytopeniaGATA2 Transcription Factor

Identifiers

PMID25676417
OpenAlexW2095384047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.